Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
Table 5
Cox proportional hazard model for OS in KRAS wild-type mCRC patients.
Click through the PLOS taxonomy to find articles in your field.
For more information about PLOS Subject Areas, click here.
Cox proportional hazard model for OS in KRAS wild-type mCRC patients.